Neuropathy — Clinical Documentation Guide (2026)

🔍 Definition

Neuropathy refers to functional disturbance or pathological change in the peripheral nervous system — encompassing a broad spectrum of disorders affecting sensory, motor, and/or autonomic nerve fibers. The term encompasses mononeuropathy (single-nerve involvement), mononeuropathy multiplex (multiple non-contiguous nerves), and polyneuropathy (diffuse, often length-dependent involvement of multiple nerves). Peripheral nerves may be damaged by metabolic insults, immune-mediated mechanisms, toxic exposures, hereditary defects, compressive/entrapment forces, ischemia, infiltration, or infection.

From a coding perspective, neuropathy is never acceptably documented as a single stand-alone diagnosis without clarifying the etiology, pattern, and fiber type when known. The FY2026 ICD-10-CM Official Guidelines require coders to reflect the underlying cause whenever a causal relationship is established — most critically for diabetic neuropathy, which must be coded using the “with” convention under ICD-10-CM Guideline Section I.A.15.

Clinically, neuropathy is divided into:

• Large-fiber neuropathy: Impairs proprioception, vibration sense, deep tendon reflexes; detected on nerve conduction velocity (NCV) studies.
• Small-fiber neuropathy (SFN): Affects pain and temperature fibers (Aδ and C fibers); NCV/EMG are typically normal; diagnosis requires skin punch biopsy for intraepidermal nerve fiber density (IENFD) or quantitative sensory testing.
• Autonomic neuropathy: Involves the autonomic nervous system; may cause orthostatic hypotension, gastroparesis, neurogenic bladder, sudomotor dysfunction.

🗂️ Alternative Terminology

Clinicians, patients, and referring providers use many terms to describe neuropathy. Coders and CDI specialists must recognize lay and clinical synonyms to query appropriately and assign the correct code.

🩺 Signs & Symptoms

Symptoms vary substantially by fiber type and distribution. Thorough documentation of the symptom constellation guides code specificity and supports medical necessity for electrodiagnostic studies.

Sensory Symptoms

• Numbness, tingling, or “pins and needles” (paresthesia) — typically distal/stocking-glove in polyneuropathy
• Burning pain, allodynia, hyperalgesia — common in small-fiber predominant neuropathy and CIDP
• Loss of proprioception and vibration sense → sensory ataxia, positive Romberg sign
• Loss of pain/temperature sensation (small fiber) → risk of unnoticed wounds

Motor Symptoms

• Distal muscle weakness (foot drop in peroneal neuropathy, wrist drop in radial neuropathy)
• Atrophy of intrinsic hand muscles (ulnar/median neuropathy)
• Hyporeflexia or areflexia (ankle jerks lost early in length-dependent polyneuropathy)
• Fasciculations in severe axonal loss

Autonomic Symptoms

• Orthostatic hypotension, dizziness on standing
• Gastroparesis, constipation or diarrhea, nausea
• Neurogenic bladder (hesitancy, retention, incontinence)
• Anhidrosis or gustatory sweating
• Sexual dysfunction; fixed heart rate (cardiovascular autonomic neuropathy)

Entrapment / Mononeuropathy-Specific

• Carpal tunnel: nocturnal hand paresthesias, thenar atrophy, positive Tinel/Phalen signs
• Ulnar neuropathy: ring/little finger numbness, intrinsic weakness, claw hand
• Peroneal neuropathy: foot drop, steppage gait
• Sciatic neuropathy: posterior thigh/leg pain, weakness of knee flexion and all distal muscles
• Meralgia paresthetica: anterolateral thigh burning/numbness, no motor deficit

🧭 Differential Diagnosis

Accurate code assignment requires distinguishing neuropathy type and etiology. The following differentials are commonly encountered in inpatient, outpatient, and post-acute settings.

📋 Clinical Indicators for Coders/CDI

The following indicators, when present in documentation, support specific neuropathy code assignment and justify diagnostic procedures, treatments, and higher resource utilization levels.

🦴 Anatomy & Pathophysiology

The peripheral nervous system (PNS) consists of all neural structures outside the brain and spinal cord: cranial nerves (III–XII), spinal nerve roots, dorsal root ganglia, peripheral nerve trunks, plexuses, and the autonomic nervous system. Peripheral nerves are composed of:

• Large myelinated fibers (Aα, Aβ): Motor function, proprioception, vibration, and light touch.
• Small myelinated fibers (Aδ): Sharp pain, temperature, and some autonomic fibers.
• Unmyelinated fibers (C fibers): Burning pain, temperature, and postganglionic autonomic fibers (sudomotor, vasomotor, cardiac).

Major Pathophysiological Mechanisms

• Axonal degeneration: Direct axon injury (metabolic, toxic, ischemic); length-dependent (longest fibers affected first); Wallerian degeneration; slow/incomplete recovery. Seen in diabetic, toxic, and nutritional neuropathies.
• Segmental demyelination: Myelin sheath breakdown; conduction slowing on NCS; can be immune-mediated (CIDP, GBS) or hereditary (CMT type 1). Remyelination possible with treatment.
• Mixed axonal-demyelinating: Most common pattern in chronic polyneuropathies; seen in CIDP, severe diabetic neuropathy.
• Compression/entrapment: Mechanical focal demyelination then axon loss at anatomical tunnels (carpal tunnel, cubital tunnel, tarsal tunnel, fibular head).
• Immune-mediated: Antibody-mediated (anti-ganglioside antibodies in GBS/MMN, anti-CNTN1 in CIDP variants); complement activation; T-cell infiltration.
• Metabolic: Hyperglycemia → advanced glycation end-products (AGEs), polyol pathway activation, oxidative stress, mitochondrial dysfunction → nerve ischemia and axon loss in diabetic neuropathy per ADA Standards of Care.
• Vasculitic: Nerve ischemia from epineurial vessel inflammation → mononeuropathy multiplex pattern; requires nerve biopsy for definitive diagnosis.

Anatomical Entrapment Sites

• Median nerve: carpal tunnel (wrist), pronator syndrome (forearm), anterior interosseous syndrome
• Ulnar nerve: cubital tunnel (elbow), Guyon’s canal (wrist)
• Radial nerve: spiral groove (wrist drop), posterior interosseous nerve at radial tunnel
• Common peroneal (fibular) nerve: fibular head — most common lower limb entrapment
• Tibial nerve: tarsal tunnel (medial ankle)
• Lateral femoral cutaneous nerve: inguinal ligament → meralgia paresthetica

💊 Medication Impact / Treatment

Pharmacologic management of neuropathy varies substantially by etiology and must be reflected in documentation to support medical necessity and accurate HCC risk adjustment.

Pain / Symptom Management

• Gabapentinoids: Gabapentin (Neurontin), pregabalin (Lyrica) — first-line for painful neuropathy per AAN guidelines; supports documentation of “painful neuropathy”
• SNRIs: Duloxetine (Cymbalta) — FDA-approved for diabetic peripheral neuropathic pain; documents severity and treatment
• TCAs: Amitriptyline, nortriptyline — second-line; document pain level and response
• Topical agents: Capsaicin 8% patch (Qutenza) — CPT 64616 for application; used for focal neuropathic pain; HCPCS J0291 for capsaicin 8% patch
• Opioids: Third-line; document refractory nature and prior treatment failures
• Lidocaine patches: Topical; limited evidence; document as adjunct

Disease-Modifying / Etiology-Specific

• IVIG (Intravenous Immunoglobulin): Standard of care for GBS (acute), CIDP (maintenance), MMN; AAN Practice Advisory; HCPCS J1569 (Gammagard Liquid 500 mg) per infusion visit
• Plasma exchange (plasmapheresis): GBS, CIDP; documents severity — typically inpatient; MS-DRG 023–024
• Corticosteroids: Prednisone or IV methylprednisolone for CIDP; document diagnosis and response
• Subcutaneous immunoglobulin (SCIG): Home maintenance for CIDP; J1561 (Gamunex) or J1569
• Rituximab: Refractory CIDP, anti-MAG neuropathy, vasculitic neuropathy; J9310
• Vitamin B12 (cyanocobalamin): B12-deficiency neuropathy; J3420 (IM injection); document deficiency etiology (D51.0 pernicious anemia vs E53.8)
• Thiamine (B1): Alcoholic neuropathy co-treatment; document alcohol use disorder + nutritional deficiency
• Glycemic optimization: Primary modifier for diabetic neuropathy; document HbA1c trend, insulin/oral agents, and complication stabilization or progression

Chemotherapy-Induced Neuropathy (CIPN)

Document the specific offending agent (taxane, platinum, vinca alkaloid, bortezomib, thalidomide) to code G62.0 with an appropriate adverse effect T-code. Dose modification or discontinuation of chemotherapy due to neuropathy must be documented by the oncologist and reflected in coding for episode-of-care reporting. Per ASCO guidelines, duloxetine is the only agent with moderate evidence for CIPN pain relief.

Preview ends here. The full guide continues with FY2026 ICD-10-CM code sets, CPT surgical coding, MS-DRG mapping, reimbursement guidance, CDI query templates, and an audit checklist — all available to CCO Members.

← Back to All Clinical Documentation Guides

📘 ICD-10-CM Guidelines (FY2026)

Section I.A.15 — “With” Convention (Diabetic Neuropathy)

Under FY2026 ICD-10-CM Official Guidelines Section I.A.15, the word “with” in a code title or instructional note establishes a presumed causal relationship between two conditions. When a patient with any type of diabetes mellitus has documented neuropathy and both conditions are listed in the medical record, coders must assign the diabetic neuropathy combination code (E08.4x–E13.4x) — even if the provider does not explicitly state “due to diabetes.” The provider need not use the exact phrase “due to diabetes”; documentation of both conditions in the same encounter is sufficient. Exception: If the provider explicitly states the neuropathy is NOT related to diabetes, that provider’s statement governs.

Code-Also and Etiology/Manifestation Convention

• Polyneuropathy in diseases classified elsewhere (G63): Always a manifestation code; requires an underlying condition code first (e.g., vasculitis M30-M31.x, amyloidosis E85.x, hypothyroidism E03.x, sarcoidosis D86.x, paraneoplastic — code neoplasm first).
• Post-herpetic neuropathy: Use B02.22 (postherpetic trigeminal neuralgia) or B02.29 (other postherpetic nervous system involvement including polyneuropathy). G53.0 (postherpetic trigeminal neuralgia) is an alternative; ICD-10-CM index directs “Post-herpetic neuralgia” → B02.29 for most sites.
• Drug-induced neuropathy (G62.0): “Code first” (T36–T65) adverse effect or poisoning code. For correctly prescribed medications causing neuropathy, use the adverse effect T-code with 5th character A (initial), D (subsequent), or S (sequela). Example: Paclitaxel neuropathy → G62.0 + T45.1x5A.
• Toxic neuropathy (G62.2): “Code first” (T51–T65) toxic substance. Example: Lead neuropathy → G62.2 + T56.0x1A.
• Radiation-induced neuropathy (G62.82): Code also Y84.2 (radiological procedure as cause) or use appropriate external cause code when applicable.
• Vitamin B12 deficiency neuropathy: Subacute combined degeneration of spinal cord G32.0 — code also E53.8 (B12 deficiency) and D51.x (if associated anemia). Sequence by documentation of principal diagnosis.
• Critical illness polyneuropathy (G62.81): Code also the critical illness (sepsis A41.x, systemic inflammatory response syndrome, ARDS J80) that caused the neuropathy.

Mononeuropathy Laterality

Most mononeuropathy codes under G56–G57 require laterality: 0 = unspecified side, 1 = right, 2 = left. Coders must query for side documentation when the clinical record is unclear. Bilateral involvement may require two codes (one for each side) unless an unspecified bilateral code exists in the tabular list.

Small Fiber Neuropathy (SFN) — No Dedicated Code

FY2026 ICD-10-CM does not contain a specific code for small fiber neuropathy. Assignment depends on etiology: idiopathic/cryptogenic SFN → G60.3 (idiopathic progressive neuropathy) or G62.89 (other specified polyneuropathy); SFN in diabetes → E11.4x; SFN in autoimmune disease → G63 + underlying condition. Document IENFD result (fibers/mm), skin biopsy site, and diagnosis statement to support specificity.

Autonomic Neuropathy Coding

Autonomic neuropathy codes fall under both Chapter 6 (G90.x) and the diabetes combination codes (E11.43, E08.43, etc.). When autonomic neuropathy is diabetic in etiology, use the E-code combination (E11.43 = Type 2 DM with diabetic autonomic neuropathy). Assign G90.x codes for non-diabetic autonomic disorders: G90.3 (multi-system atrophy with orthostatic hypotension — Shy-Drager), G90.1 (familial dysautonomia/Riley-Day), G90.09 (other idiopathic peripheral autonomic neuropathy).

🔢 ICD-10-CM Code Set (FY2026)

All codes verified against the FY2026 ICD-10-CM Tabular List and Index (CMS.gov) effective October 1, 2025.

G56 — Mononeuropathies of Upper Limb

G57 — Mononeuropathies of Lower Limb

G58 / G59 — Other Mononeuropathies

G60 — Hereditary and Idiopathic Neuropathy

G61 — Inflammatory Polyneuropathies

G62 — Other and Unspecified Polyneuropathies

G63, G64 — Polyneuropathy / Neuromuscular Disorders in Other Diseases

Diabetic Neuropathy — E-Code Combination Codes

Autonomic Nervous System (G90.x) and Related

🔎 Indexing

Use the FY2026 ICD-10-CM Alphabetic Index primary entry for neuropathy. Key index paths:

• Neuropathy, neuropathic — main term → subterm “peripheral” → subterm by etiology (alcoholic, diabetic, drug-induced, hereditary, idiopathic, inflammatory, ischemic, toxic)
• Neuropathy, peripheral, diabetic → see E08–E13 with .40–.49
• Polyneuropathy — main term → subterms by etiology (alcoholic G62.1, critical illness G62.81, diabetic [see Diabetes, with neuropathy], drug-induced G62.0, hereditary G60.x, idiopathic G60.9, inflammatory G61.x, radiation G62.82, toxic G62.2)
• Syndrome, carpal tunnel → G56.0-
• Syndrome, tarsal tunnel → G57.5-
• Syndrome, Guillain-Barré → G61.0
• Neuropathy, CIDP → G61.81
• Disease, Charcot-Marie-Tooth → G60.0
• Meralgia paresthetica → G57.1-
• Neuralgia, post-herpetic → B02.29 (other PHN) or B02.22 (trigeminal)
• Degeneration, subacute combined → G32.0
• Dysautonomia → G90.1 (familial), G90.09 (other idiopathic)
• Syndrome, Refsum → G60.1

🏥 CPT (2026)

All CPT codes verified against the AMA CPT 2026 Professional Edition. Note: CPT codes 95900, 95903, 95904 were deleted in prior years and replaced by 95907–95913 and 95885–95887.

🧾 HCPCS (2026)

HCPCS codes verified against the CMS HCPCS 2026 Annual Update.

📚 AHA Coding Clinic (Recent Guidance)

The following represents AHA Coding Clinic guidance relevant to neuropathy coding. Coders should reference original Coding Clinic issues for complete context; summaries below reflect key principles.

💰 HCC / Risk Adjustment (v28)

HCC mappings below reflect CMS-HCC Model v28 (CY2026 MA risk adjustment). Diabetic neuropathy codes carry the highest RAF impact in this category due to HCC 37 (Diabetes with Complications).

✍️ CDI Query Templates

All queries follow AHIMA/ACDIS 2019 Query Practice Brief standards: non-leading, multiple-choice format, clinical indicators stated, timeframe specified.

🧑‍⚕️ Treatments (Clinical)

Treatment documentation supports medical necessity, resource utilization coding, and HCC accuracy. CDI specialists should ensure all active treatments are reflected in the diagnosis documentation.

Entrapment / Compressive Mononeuropathies

• Conservative: wrist splinting (CTS), activity modification, NSAIDs, corticosteroid injection (CPT 20526 CTS injection)
• Surgical decompression: carpal tunnel release (CPT 64721), cubital tunnel decompression/transposition (CPT 64718), tarsal tunnel release (CPT 28035), peroneal nerve decompression
• Post-surgical documentation: note surgical findings, nerve condition, expected recovery timeline

Diabetic Neuropathy

• Glycemic optimization (primary modifier for progression); document HbA1c target and achieved level
• Symptomatic pain management: pregabalin, gabapentin, duloxetine (FDA-approved for DPN), TCAs
• Foot care: preventive podiatry, custom diabetic footwear (HCPCS A5500–A5513), monofilament testing
• Cardiovascular autonomic: fludrocortisone, midodrine for orthostatic hypotension; document standing BP measurements

CIDP / Immune-Mediated Neuropathies

• IVIG: first-line; Gammagard Liquid (J1569), Gamunex-C (J1561); document loading vs maintenance dose, response assessment
• Subcutaneous immunoglobulin (SCIG): home maintenance alternative; Hizentra (J1720), Gamunex (J1561)
• Plasma exchange: second-line acute; document number of exchanges, volume treated
• Oral corticosteroids or pulse IV methylprednisolone: document dose, duration, taper
• Rituximab (J9310): refractory cases; document CD20+ B-cell depletion strategy
• Physical and occupational therapy: document functional deficits, goals, frequency

GBS (Acute Phase)

• IVIG 2 g/kg over 5 days OR plasma exchange 5 exchanges over 10–14 days (equivalent efficacy per Dutch GBS Study Group)
• ICU monitoring: respiratory function (FVC, NIF), autonomic monitoring, DVT prophylaxis
• Mechanical ventilation when FVC <15–20 mL/kg: ICD-10-PCS 5A1935Z (continuous IMV >96 h) — highest MS-DRG weight tier
• Pain management: gabapentin, opioids for neuropathic pain during acute phase
• Rehab: early PT/OT; long-term recovery may require inpatient rehabilitation (IRF) coding

Hereditary Neuropathy (CMT)

• No disease-modifying therapy currently available; symptom management and orthotic support
• AFO for foot drop (L-code orthoses), custom footwear, surgery for foot deformity (pes cavus correction)
• Genetic counseling: document gene mutation identified (PMP22 duplication CMT1A, GJB1 CMTX, MFN2 CMT2A)
• Avoid neurotoxic drugs (vincristine, colchicine) — document CMT diagnosis prominently in medication reconciliation

🎓 Patient Education / Summary

Patient education documentation supports coding specificity and demonstrates active management of neuropathy complications. When education is documented in the medical record, coders can confirm the diagnosis was recognized and addressed during the encounter.

Key Patient Education Points

• Foot care for diabetic neuropathy: Daily foot inspection, proper footwear, avoidance of barefoot walking, prompt reporting of wounds or skin breakdown. Lack of pain sensation means injuries may go unnoticed — patient and caregiver education is critical to preventing diabetic foot ulcers (E11.621–E11.629, HCC 18/19).
• Medication adherence: Explain the role of gabapentinoids and duloxetine in neuropathic pain modulation (not traditional pain relievers); address side effects (drowsiness, weight gain) that affect adherence.
• IVIG home vs. infusion center: For CIDP/MMN patients transitioning to SCIG, educate on self-injection technique, site rotation, recognizing adverse reactions, and storage requirements.
• Avoidance of neurotoxic exposures: Alcohol (G62.1 — document counseling); neurotoxic medications (document medication reconciliation); occupational exposures (repetitive wrist use for CTS, tight compression garments).
• Activity and rehabilitation: Balance training, fall prevention (loss of proprioception increases fall risk — Z91.81 fall risk); assistive devices (cane, walker, AFO); swimming and low-impact exercise for CMT/polyneuropathy.
• When to call the physician: GBS warning signs — rapid spread of weakness, breathing difficulty, swallowing problems require immediate emergency evaluation; educate post-GBS patients on relapse vs. CIDP development (~3–5% of GBS develop CIDP).
• Genetic counseling (hereditary neuropathy): CMT is autosomal dominant (CMT1A/1B) or X-linked (CMTX) in most cases; family members at 50% risk for AD forms; refer to genetic counselor and Charcot-Marie-Tooth Association for resources.

Lay Summary for Documentation

Neuropathy is damage or disease affecting the nerves outside the brain and spinal cord. Depending on which nerves are affected, it can cause numbness, tingling, burning pain, weakness, or problems with automatic body functions like blood pressure, digestion, or bladder control. The most common cause is diabetes, but neuropathy can also result from immune system attacks, inherited conditions, vitamin deficiencies, certain medications, alcohol, and many other conditions. Treatment focuses on addressing the underlying cause, controlling symptoms, and preventing complications — particularly foot injuries in patients with diabetes who cannot feel pain normally.

Documentation completeness — including etiology, nerve distribution, fiber type, and response to treatment — is essential for accurate ICD-10-CM coding, appropriate HCC risk capture, and demonstration of quality care to payers and accreditors.

About this Guide

This Clinical Documentation Guide is published by CCO Academy and is intended for credentialed coding, CDI, and clinical documentation professionals. Content is updated for FY2026 ICD-10-CM (effective October 1, 2025). All code assignments should be verified against the official ICD-10-CM Tabular List, AHA Coding Clinic, and applicable payer-specific policies. This guide does not constitute legal, medical, or compliance advice.

Last reviewed: April 2026 · Next scheduled review: October 2026 (FY2027 update)